The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients

A pilot open-labeled prospective study

Atsushi Sakuraba, Toshiro Sato, Hidehiko Matsukawa, Susumu Okamoto, Hiromasa Takaishi, Haruhiko Ogata, Yasushi Iwao, Toshifumi Hibi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose Crohn's disease (CD) commonly recurs after surgery, and a number of patients need repeated surgery, especially smokers and those with repeated surgeries or penetrating disease. Whether infliximab prevents postsurgical recurrence in high-risk CD remains unknown. In the present pilot openlabeled study, we investigated the safety and efficacy of scheduled infliximab, which was started early after surgery, in maintaining remission of CD patients who have undergonemultiple surgeries due to penetrating disease. Methods Eleven patients (nine male, two female; age range, 26-48 years) who had undergone repeated surgeries (median, 4; range, 2-5) for penetrating disease were enrolled. Two to 4 weeks after surgery, the patients were started on intravenous infliximab (5 mg/kg) at an 8-week interval. The primary end points were the proportion of patients in clinical remission at the end of the study, the rate of endoscopic/ radiologic remission at 24 months, and the rate of adverse effects. Results One patient dropped out due to non-compliance, and ten patients were eligible for analysis. Clinical remission was maintained in six of ten patients (60.0%) at the end of the study. At 24 months, four out of ten patients were in endoscopic or radiological remission (40.0%). Two patients experienced adverse effects (18.2%), one of whom elected to withdraw from the study. Conclusion The findings of no major safety concern and possible clinical benefit in our study suggest that further investigation of infliximab as a treatment for prevention of postsurgical recurrence in high-risk CD is warranted.

Original languageEnglish
Pages (from-to)947-952
Number of pages6
JournalInternational Journal of Colorectal Disease
Volume27
Issue number7
DOIs
Publication statusPublished - 2012 Jul

Fingerprint

Crohn Disease
Prospective Studies
Recurrence
Safety
Infliximab
Patient Compliance

Keywords

  • Crohn's disease
  • Infliximab
  • Maintenance
  • Postsurgical recurrence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{359129e3ae4c496083a97ddb3eae70aa,
title = "The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: A pilot open-labeled prospective study",
abstract = "Purpose Crohn's disease (CD) commonly recurs after surgery, and a number of patients need repeated surgery, especially smokers and those with repeated surgeries or penetrating disease. Whether infliximab prevents postsurgical recurrence in high-risk CD remains unknown. In the present pilot openlabeled study, we investigated the safety and efficacy of scheduled infliximab, which was started early after surgery, in maintaining remission of CD patients who have undergonemultiple surgeries due to penetrating disease. Methods Eleven patients (nine male, two female; age range, 26-48 years) who had undergone repeated surgeries (median, 4; range, 2-5) for penetrating disease were enrolled. Two to 4 weeks after surgery, the patients were started on intravenous infliximab (5 mg/kg) at an 8-week interval. The primary end points were the proportion of patients in clinical remission at the end of the study, the rate of endoscopic/ radiologic remission at 24 months, and the rate of adverse effects. Results One patient dropped out due to non-compliance, and ten patients were eligible for analysis. Clinical remission was maintained in six of ten patients (60.0{\%}) at the end of the study. At 24 months, four out of ten patients were in endoscopic or radiological remission (40.0{\%}). Two patients experienced adverse effects (18.2{\%}), one of whom elected to withdraw from the study. Conclusion The findings of no major safety concern and possible clinical benefit in our study suggest that further investigation of infliximab as a treatment for prevention of postsurgical recurrence in high-risk CD is warranted.",
keywords = "Crohn's disease, Infliximab, Maintenance, Postsurgical recurrence",
author = "Atsushi Sakuraba and Toshiro Sato and Hidehiko Matsukawa and Susumu Okamoto and Hiromasa Takaishi and Haruhiko Ogata and Yasushi Iwao and Toshifumi Hibi",
year = "2012",
month = "7",
doi = "10.1007/s00384-011-1398-y",
language = "English",
volume = "27",
pages = "947--952",
journal = "International Journal of Colorectal Disease",
issn = "0179-1958",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients

T2 - A pilot open-labeled prospective study

AU - Sakuraba, Atsushi

AU - Sato, Toshiro

AU - Matsukawa, Hidehiko

AU - Okamoto, Susumu

AU - Takaishi, Hiromasa

AU - Ogata, Haruhiko

AU - Iwao, Yasushi

AU - Hibi, Toshifumi

PY - 2012/7

Y1 - 2012/7

N2 - Purpose Crohn's disease (CD) commonly recurs after surgery, and a number of patients need repeated surgery, especially smokers and those with repeated surgeries or penetrating disease. Whether infliximab prevents postsurgical recurrence in high-risk CD remains unknown. In the present pilot openlabeled study, we investigated the safety and efficacy of scheduled infliximab, which was started early after surgery, in maintaining remission of CD patients who have undergonemultiple surgeries due to penetrating disease. Methods Eleven patients (nine male, two female; age range, 26-48 years) who had undergone repeated surgeries (median, 4; range, 2-5) for penetrating disease were enrolled. Two to 4 weeks after surgery, the patients were started on intravenous infliximab (5 mg/kg) at an 8-week interval. The primary end points were the proportion of patients in clinical remission at the end of the study, the rate of endoscopic/ radiologic remission at 24 months, and the rate of adverse effects. Results One patient dropped out due to non-compliance, and ten patients were eligible for analysis. Clinical remission was maintained in six of ten patients (60.0%) at the end of the study. At 24 months, four out of ten patients were in endoscopic or radiological remission (40.0%). Two patients experienced adverse effects (18.2%), one of whom elected to withdraw from the study. Conclusion The findings of no major safety concern and possible clinical benefit in our study suggest that further investigation of infliximab as a treatment for prevention of postsurgical recurrence in high-risk CD is warranted.

AB - Purpose Crohn's disease (CD) commonly recurs after surgery, and a number of patients need repeated surgery, especially smokers and those with repeated surgeries or penetrating disease. Whether infliximab prevents postsurgical recurrence in high-risk CD remains unknown. In the present pilot openlabeled study, we investigated the safety and efficacy of scheduled infliximab, which was started early after surgery, in maintaining remission of CD patients who have undergonemultiple surgeries due to penetrating disease. Methods Eleven patients (nine male, two female; age range, 26-48 years) who had undergone repeated surgeries (median, 4; range, 2-5) for penetrating disease were enrolled. Two to 4 weeks after surgery, the patients were started on intravenous infliximab (5 mg/kg) at an 8-week interval. The primary end points were the proportion of patients in clinical remission at the end of the study, the rate of endoscopic/ radiologic remission at 24 months, and the rate of adverse effects. Results One patient dropped out due to non-compliance, and ten patients were eligible for analysis. Clinical remission was maintained in six of ten patients (60.0%) at the end of the study. At 24 months, four out of ten patients were in endoscopic or radiological remission (40.0%). Two patients experienced adverse effects (18.2%), one of whom elected to withdraw from the study. Conclusion The findings of no major safety concern and possible clinical benefit in our study suggest that further investigation of infliximab as a treatment for prevention of postsurgical recurrence in high-risk CD is warranted.

KW - Crohn's disease

KW - Infliximab

KW - Maintenance

KW - Postsurgical recurrence

UR - http://www.scopus.com/inward/record.url?scp=84864457761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864457761&partnerID=8YFLogxK

U2 - 10.1007/s00384-011-1398-y

DO - 10.1007/s00384-011-1398-y

M3 - Article

VL - 27

SP - 947

EP - 952

JO - International Journal of Colorectal Disease

JF - International Journal of Colorectal Disease

SN - 0179-1958

IS - 7

ER -